Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $41.00.

A number of equities analysts have commented on ACRS shares. BTIG Research started coverage on shares of Aclaris Therapeutics in a research note on Thursday, October 6th. They issued a “buy” rating and a $32.00 target price on the stock. StockNews.com began coverage on shares of Aclaris Therapeutics in a report on Wednesday, October 12th. They set a “sell” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Aclaris Therapeutics in a research note on Monday, August 1st. Finally, SVB Leerink reissued an “outperform” rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $17.70 on Friday. The company has a market capitalization of $1.18 billion, a P/E ratio of -13.72 and a beta of 0.55. The company’s 50-day simple moving average is $15.90 and its two-hundred day simple moving average is $15.30. Aclaris Therapeutics has a one year low of $9.26 and a one year high of $18.96.

Insider Buying and Selling

In related news, insider Joseph Monahan sold 5,000 shares of the business’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $15.98, for a total transaction of $79,900.00. Following the transaction, the insider now directly owns 101,386 shares in the company, valued at approximately $1,620,148.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Joseph Monahan sold 5,000 shares of the business’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $15.98, for a total transaction of $79,900.00. Following the transaction, the insider now directly owns 101,386 shares in the company, valued at approximately $1,620,148.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Andrew N. Schiff sold 37,839 shares of the business’s stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $16.54, for a total value of $625,857.06. Following the transaction, the director now owns 588,916 shares in the company, valued at $9,740,670.64. The disclosure for this sale can be found here. Insiders have sold a total of 99,639 shares of company stock worth $1,644,933 in the last ninety days. 6.70% of the stock is owned by insiders.

Institutional Trading of Aclaris Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in Aclaris Therapeutics by 3.4% during the 1st quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company’s stock valued at $98,789,000 after purchasing an additional 190,985 shares during the last quarter. BlackRock Inc. grew its stake in Aclaris Therapeutics by 3.0% during the 3rd quarter. BlackRock Inc. now owns 4,810,298 shares of the biotechnology company’s stock valued at $75,714,000 after purchasing an additional 140,382 shares during the last quarter. Vanguard Group Inc. grew its stake in Aclaris Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,931,709 shares of the biotechnology company’s stock valued at $46,145,000 after purchasing an additional 118,024 shares during the last quarter. Commodore Capital LP grew its stake in Aclaris Therapeutics by 4.1% during the 2nd quarter. Commodore Capital LP now owns 2,410,622 shares of the biotechnology company’s stock valued at $33,652,000 after purchasing an additional 95,974 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Aclaris Therapeutics by 6.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,853,251 shares of the biotechnology company’s stock valued at $29,170,000 after purchasing an additional 119,351 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Recommended Stories

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.